Importantly, we have observed that RFA reduces intracellular levels of HSP70 by promoting its translocation and that of TRAIL-R2 to the cell surface in a dose-response manner (Fig. 4C), which may make the tumor a better target for TRAIL-mediated immune attack. This evidence concerns the gene TNFRSF10B and neoplasm.